Side-by-side · Research reference

LiraglutidevsPEG-MGF

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedFlagship14/45 cited

BAnimal-MechanisticHUMAN-REVIEWED2/69 cited

Liraglutide

Daily GLP-1 RA · FDA-Approved

0.6–3.0 mgDaily doseSAXENDA (liraglutide) injectio 2014

5–10%Body-weight ↓SAXENDA (liraglutide) injectio 2014

~13 hrHalf-lifeSAXENDA (liraglutide) injectio 2014

SQ · Abdomen / thigh / arm · Once daily

PEG-MGF

IGF-1Ec Splice Variant · PEGylated

~2 hrHalf-life (PEG)

~7 minNative MGF t½

IGF-1EcSplice variant

SQ · Research Protocol

01Mechanism of Action

Parameter

Liraglutide

PEG-MGF

Primary target

GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014

IGF-1 receptor on muscle satellite cells and myocytes

Pathway

GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014 Marso 2016

IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion

Downstream effect

Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016

Satellite cell activation, muscle fiber repair, localized hypertrophy signaling

Feedback intact?

Glucose-dependent insulin release preserves physiological feedback

Partially bypassed — does not require hepatic IGF-1 synthesis

Origin

Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014

IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation

Antibody development

—

Unknown — no long-term human immunogenicity data

02Dosage Protocols

Parameter

Liraglutide

PEG-MGF

Standard dose (T2D, Victoza)

1.2–1.8 mg / daySAXENDA (liraglutide) injectio 2014

—

Standard dose (weight, Saxenda)

3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014

—

Frequency

Once daily, same time each day

Post-training or daily

Timing to match endogenous MGF pulse post-exercise.

Titration schedule

0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks

Mitigates GI side effects.

—

Evidence basis

FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016 SAXENDA (liraglutide) injectio 2014

Animal / mechanistic

Duration

Indefinite for chronic indication

—

Reconstitution

Pre-filled commercial pen (no reconstitution)

Sterile bacteriostatic water

Lyophilized form; store reconstituted at 2–8 °C.

Timing

Any time of day; consistent

Within 30–60 min post-training

Aligns with endogenous MGF window.

Half-life

~13 hrSAXENDA (liraglutide) injectio 2014

~2 hours (PEGylated)

Native MGF: ~7 min; PEGylation extends circulation.

Research dose range

—

100–200 mcg

Extrapolated from animal models; no validated human protocols.

PEG molecular weight

—

Typically 5–30 kDa

Higher MW = longer t½, greater steric hindrance.

03Metabolic / Fat Loss Evidence

Parameter

Liraglutide

PEG-MGF

Primary target

—

Muscle tissue (satellite cells, myocytes) — not adipose-specific

Indirect metabolic effect

—

IGF-1 signaling may modulate insulin sensitivity and lipid metabolismRen 2015

Mechanism distinct from direct lipolytic peptides.

Body composition

—

Lean mass preservation / hypertrophy focus

Fat loss evidence

—

No direct human or animal RCT data for PEG-MGF-driven fat reduction

04Side Effects & Safety

Parameter

Liraglutide

PEG-MGF

GI symptoms

Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014

—

Pancreatitis risk

Rare; discontinue if suspected

—

Thyroid C-cell tumours

Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014

—

Hypoglycemia

Low risk as monotherapy; elevated with sulfonylureas / insulin

—

Heart rate

Modest ↑ resting HR (~2-3 bpm)

—

Cardiovascular benefit

↓ MACE in high-risk T2D (LEADER trial)Marso 2016

—

Pregnancy / OB

Contraindicated

—

Injection site reaction

—

Erythema, induration (common with SQ peptides)

Hypoglycemia risk

—

IGF-1 axis activation can lower blood glucose

IGF-1R overstimulation

—

Theoretical risk of aberrant cell proliferation with chronic supraphysiological exposure

Fluid retention

—

Possible with IGF-1 pathway activation (dose-dependent)

PEG accumulation

—

Chronic high-dose PEGylated proteins may accumulate in tissues; clearance slower in renal impairment

Antibody formation

—

PEGylated proteins can elicit anti-PEG antibodies (neutralizing potential unknown)

Cancer risk

—

IGF-1 axis stimulation contraindicated in active malignancy

Human safety data

—

Absent — no published human trials for PEG-MGF

Absolute Contraindications

Liraglutide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to liraglutide

PEG-MGF

·Active malignancy or history of cancer (IGF-1R proliferative signaling)
·Known hypersensitivity to PEGylated compounds
·Pregnancy / lactation (no reproductive toxicity data)

Relative Contraindications

Liraglutide

·Severe gastroparesis
·History of pancreatitis
·Severe gastrointestinal disease

PEG-MGF

·Diabetes (monitor glucose closely)
·Renal impairment (PEG clearance reduced)
·Retinopathy (IGF-1 axis effects on vascular proliferation)

05Administration Protocol

Parameter

Liraglutide

PEG-MGF

1. Reconstitution / device

Commercial pre-filled pen, no reconstitution required.

Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate sites.

Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.

3. Timing

Once daily, same time each day. Take with or without food.

Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.

4. Storage

Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.

Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.

5. Needle

Pen-supplied 32G needle.

29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.

06Stack Synergy

Liraglutide

— no documented stacks

PEG-MGF

+ BPC-157

Moderate

View BPC-157 →

BPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.

PEG-MGF: 100–200 mcg SQ post-training
BPC-157: 250–500 mcg SQ or oral, twice daily
Duration: 4–6 weeks (injury-dependent)
Primary benefit: Accelerated muscle and connective tissue repair, enhanced recovery

+ TB-500

Strong

View TB-500 →

TB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.

PEG-MGF: 100–200 mcg SQ post-training
TB-500: 2–5 mg SQ, 2× per week (loading), then weekly
Timing: Stagger injections by 6–12 hours
Primary benefit: Maximal satellite cell recruitment and myogenic differentiation, injury repair